| 18.37 -0.5 (-2.65%) | 03-13 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 22.18  |
1-year : | 23.65 |
| Resists | First : | 18.99 |
Second : | 20.25 |
| Pivot price | 19.1 |
|||
| Supports | First : | 16.95 |
Second : | 14.11 |
| MAs | MA(5) : | 18.97 |
MA(20) : | 19.34 |
| MA(100) : | 19.97 |
MA(250) : | 28.21 |
|
| MACD | MACD : | 0 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 53.6 |
D(3) : | 62 |
| RSI | RSI(14): 44.7 |
|||
| 52-week | High : | 44.34 | Low : | 15.96 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ZLAB ] has closed above bottom band by 15.6%. Bollinger Bands are 50.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 10 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 18.96 - 19.12 | 19.12 - 19.22 |
| Low: | 17.95 - 18.12 | 18.12 - 18.23 |
| Close: | 18.15 - 18.41 | 18.41 - 18.58 |
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. It also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other B-celllymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, the company develops CLN-081 for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab that inhibits interactions between PD-1 and its ligands; ZL-2309, an orally active, selective, and ATP-competitive cell division cycle 7 (CDC7) kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; KarXT for the treatment of psychiatric and neurological conditions; ZL-2313, an investigational inhibitor of triple-mutant EGFR harboring; ZL-2314, an investigational inhibitor of double-mutant EGFR harboring; and Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter. Zai Lab Limited was incorporated in 2013 and is headquartered in Shanghai, China.
Sat, 14 Mar 2026
Assessing Zai Lab (ZLAB) Valuation After Prolonged Share Price Weakness And Reported Intrinsic Discount - simplywall.st
Fri, 13 Mar 2026
[144] Zai Lab Ltd SEC Filing - Stock Titan
Fri, 13 Mar 2026
ZLAB Should I Buy - Intellectia AI
Wed, 11 Mar 2026
(ZLAB) Volatility Zones as Tactical Triggers - Stock Traders Daily
Tue, 10 Mar 2026
Zai Lab Ltd Chairperson & CEO Du Ying Sells 100,000 Shares - TradingView
Fri, 06 Mar 2026
Insider Sell: Edmondson Frazor Titus III Sells Shares of Zai Lab Ltd (ZLAB) - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 111 (M) |
| Shares Float | 1,020 (M) |
| Held by Insiders | 1.7 (%) |
| Held by Institutions | 30 (%) |
| Shares Short | 3,370 (K) |
| Shares Short P.Month | 3,870 (K) |
| EPS | -1.61 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.46 |
| Profit Margin | -38.2 % |
| Operating Margin | -54.5 % |
| Return on Assets (ttm) | -12.2 % |
| Return on Equity (ttm) | -22.6 % |
| Qtrly Rev. Growth | 17 % |
| Gross Profit (p.s.) | 0.43 |
| Sales Per Share | 4.15 |
| EBITDA (p.s.) | -1.94 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -151 (M) |
| Levered Free Cash Flow | -93 (M) |
| PE Ratio | -11.49 |
| PEG Ratio | 0 |
| Price to Book value | 2.83 |
| Price to Sales | 4.41 |
| Price to Cash Flow | -13.48 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|